Measuring Synthetic Promoter Activities

Synthetic promoters to be developed for gene therapy in eye disease.

Isolating Promoter Sequences for Analysis

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, and Synpromics Limited, a leading synthetic promoter development company backed by Calculus Capital, today announced they have entered into a broad, multi-target collaboration agreement.

Synpromics Chemical Stocks

Synpromics announces that it has completed a financing round including £2.1m of new funding from Calculus Capital (“Calculus”). The funds will be used for business expansion and further development of Synpromics’ proprietary synthetic promoter technology.

Characterisation of Synthetic Promoter Activity

Synpromics Limited, a leading synthetic biology company, is pleased to announce that it has formed a collaboration with uniQure N.V., a world leader and pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene medicines to liver.